Becatecarin
- Generic Name
- Becatecarin
- Drug Type
- Small Molecule
- Chemical Formula
- C33H34Cl2N4O7
- CAS Number
- 119673-08-4
- Unique Ingredient Identifier
- A60X6MBU6G
- Background
Becatecarin is a derivative of rebeccamycin.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 248
- Registration Number
- NCT00090025
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇮🇹Policlinico Universitario di Udine, Udine, Italy
🇨🇦Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00087204
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00086983
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
- Conditions
- Extensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00084487
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00006262
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00005085
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Atlanta Cancer Care, Atlanta, Georgia, United States
🇺🇸Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2003-08-08
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00005027
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT00006017
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Brain and Central Nervous System TumorsLymphomaNeuroblastomaRetinoblastomaSarcomaUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 200
- Registration Number
- NCT00006102
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia, United States
🇺🇸Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
- Conditions
- Male Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IV Breast Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00005817
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.